Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of enzalutamide (Xtandi) to reduce morbidity in COVID-19
2020-002027-10Phase 2Terminated
- Sponsor
- Umeå University Hospital
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in coronavirus disease 2019 (COVID-19) comparing Enzalutamide (Xtandi) arm with Control arm (standard of care) (2 arms). Primary endpoints: Time to mechanical ventilation or death and Time to hospital discharge. Started Apr 2020; status: terminated.
02
Drugs
enzalutamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002027-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002027-10.